Traders should monitor the upcoming APEX Phase 2 Part A 52-week data readout this month and the head-to-head APG279 vs. Dupixent data in 2H 2026, which could serve as key catalysts if results show competitive dosing or efficacy advantages.
Price Chart
Executive Summary
Apogee Therapeutics reported full-year 2025 financial results with increased R&D and G&A spending driving a wider net loss, while maintaining a strong cash position of $902.9 million that funds operations into 2H 2028. The company highlighted upcoming clinical milestones for its lead asset zumilokibart in atopic dermatitis, asthma, and EoE, including a head-to-head trial against Dupixent with interim data expected in 2H 2026.
Key Facts
- Cash, cash equivalents, and marketable securities totaled $902.9 million as of December 31, 2025, up from $731.1 million in 2024.
- R&D expenses increased to $214.7 million in 2025 from $167.9 million in 2024.
- G&A expenses rose to $70.9 million in 2025 from $49.0 million in 2024.
- Net loss widened to $255.8 million in 2025 from $182.1 million in 2024.
- APEX Phase 2 Part A 52-week data for zumilokibart in atopic dermatitis expected in March 2026.
- Head-to-head Phase 1b trial of APG279 vs. Dupixent in AD to deliver interim data in 2H 2026.
Financial Impact
Increased operating expenses led to a 40% rise in net loss year-over-year, but cash runway extends to 2H 2028.
Risk Factors
- Clinical trial results may not meet expectations, particularly in head-to-head comparison with established therapy Dupixent.
- Increasing operating expenses without near-term revenue could pressure valuation if development timelines extend.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3247224 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 15-12G | — | awaiting T+5 | — | — |
Sep 3, 2026 29d ago | 25-NSE | $135.06 awaiting T+5 | awaiting T+5 | — | — |
Sep 3, 2026 29d ago | 8-K | $135.06 awaiting T+5 | awaiting T+5 | — | — |
Aug 11, 2026 7w ago | 8-K | $134.55 $134.71 | ▲ +0.12% | ▲ +0.56% | — |
Aug 10, 2026 7w ago | 8-K | $134.65 $134.59 | ▼ −0.04% | ▲ +0.00% | — |
Aug 10, 2026 7w ago | Press Release | $134.65 $134.59 | ▼ −0.04% | ▲ +0.00% | — |
Aug 6, 2026 8w ago | Institutional Cluster | $134.49 $134.45 | ▼ −0.03% | ▼ −1.24% | — |
Aug 3, 2026 8w ago | DEFA14A | $134.19 $134.69 | ▲ +0.37% | ▲ +0.47% | — |
Jul 11, 2026 11w ago | Insider Cluster | $133.82 $134.00 | ▲ +0.13% | ▲ +0.92% | — |
Jun 26, 2026 13w ago | DEFA14A | $132.61 $133.50 | ▲ +0.67% | ▼ −0.72% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access